A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
NCT07441980 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2026-03-02
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia(AML)
Interventions
- DRUG
-
CAR-T cells chimeric antigen receptor T cells
CT1390B cells infusion
Sponsors & Collaborators
-
Institute of Hematology & Blood Diseases Hospital, China
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-02
- Primary Completion
- 2026-12-31
- Completion
- 2028-06-30
Countries
- China
Study Locations
More Related Trials
-
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
NCT04923919 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia
NCT07432100 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
NCT04271410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05309213 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07200479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
NCT03544021 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas
NCT04196205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
NCT04803929 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
NCT04796688 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT06499025 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients
NCT03902197 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia
NCT04094766 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
NCT07316907 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML
NCT05473221 ·Status: UNKNOWN ·Phase: PHASE1
-
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT03896854 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT05016063 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
NCT04649983 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04012879 ·Status: UNKNOWN ·Phase: PHASE1
-
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
NCT04782193 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
NCT04714593 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
NCT04723901 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL
NCT05350787 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
NCT05640713 ·Status: UNKNOWN ·Phase: PHASE1